Palvella Therapeutics (PVLA) said Wednesday that first patients have been dosed in the phase 2 clinical trial of Qtorin 3.9% rapamycin anhydrous gel to treat cutaneous venous malformations.
Venous malformation is the underdevelopment of veins in the body that can lead to abnormal blood vessels.
The company said the study is expected to enroll about 15 patients at least six years old across the US to evaluate the safety and efficacy of Qtorin administered topically once daily.
According to Palvella, the US Food and Drug Administration granted fast track designation to the drug in April 2024.
Price: 14.45, Change: -0.28, Percent Change: -1.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.